Heat Shock Protein 27 Modification is Increased in the Human Diabetic Failing Heart

Gawlowski T, Stratmann B, Stork I, Engelbrecht B, Brodehl A, Niehaus K, Koerfer R, Tschoepe D, Milting H (2009)
Hormone and Metabolic Research 41(08): 594-599.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ;
Abstract / Bemerkung
Chronic conditions like diabetes mellitus (DM) leading to altered metabolism might cause cardiac dysfunction. Hyperglycemia plays an important role in the pathogenesis of diabetic complications including accumulation of methylglyoxal (MG), a highly reactive alpha-dicarbonyl metabolite of glucose degradation pathways and increased generation of advanced glycation endproducts (AGEs). The aim of this investigation was to study the extent of the MG-modification argpyrimidine in human diabetic heart and in rat cardiomyoblasts grown under hyperglycemic conditions. Left ventricular myocardial samples from explanted hearts of patients with cardiomyopathy with (n=8) or without DM (n=8) as well as nonfailing donor organs (n=6), and rat cardiac myoblasts H9c2 treated with glucose were screened for the MG-modification argpyrimidine. The small heat shock protein 27 (Hsp27) revealed to be the major argpyrimidine containing protein in cardiac tissue. Additionally, the modification of arginine leading to argpyrimidine and the phosphorylation of Hsp27 are increased in the myocardium of patients with DM. In H9c2 cells hyperglycemia leads to a decrease of the Hsp27-expression and an increase in argpyrimidine content and phosphorylation of Hsp27, which was accompanied by the induction of oxidative stress and apoptosis. This study shows an association between diabetes and increased argpyrimidine-modification of myocardial Hsp27, a protein which is involved in apoptosis, oxidative stress, and cytoskeleton stabilization.
Erscheinungsjahr
Zeitschriftentitel
Hormone and Metabolic Research
Band
41
Zeitschriftennummer
08
Seite
594-599
ISSN
eISSN
PUB-ID

Zitieren

Gawlowski T, Stratmann B, Stork I, et al. Heat Shock Protein 27 Modification is Increased in the Human Diabetic Failing Heart. Hormone and Metabolic Research. 2009;41(08):594-599.
Gawlowski, T., Stratmann, B., Stork, I., Engelbrecht, B., Brodehl, A., Niehaus, K., Koerfer, R., et al. (2009). Heat Shock Protein 27 Modification is Increased in the Human Diabetic Failing Heart. Hormone and Metabolic Research, 41(08), 594-599. doi:10.1055/s-0029-1216374
Gawlowski, T., Stratmann, B., Stork, I., Engelbrecht, B., Brodehl, A., Niehaus, K., Koerfer, R., Tschoepe, D., and Milting, H. (2009). Heat Shock Protein 27 Modification is Increased in the Human Diabetic Failing Heart. Hormone and Metabolic Research 41, 594-599.
Gawlowski, T., et al., 2009. Heat Shock Protein 27 Modification is Increased in the Human Diabetic Failing Heart. Hormone and Metabolic Research, 41(08), p 594-599.
T. Gawlowski, et al., “Heat Shock Protein 27 Modification is Increased in the Human Diabetic Failing Heart”, Hormone and Metabolic Research, vol. 41, 2009, pp. 594-599.
Gawlowski, T., Stratmann, B., Stork, I., Engelbrecht, B., Brodehl, A., Niehaus, K., Koerfer, R., Tschoepe, D., Milting, H.: Heat Shock Protein 27 Modification is Increased in the Human Diabetic Failing Heart. Hormone and Metabolic Research. 41, 594-599 (2009).
Gawlowski, T., Stratmann, B., Stork, I., Engelbrecht, B., Brodehl, A., Niehaus, Karsten, Koerfer, R., Tschoepe, D., and Milting, H. “Heat Shock Protein 27 Modification is Increased in the Human Diabetic Failing Heart”. Hormone and Metabolic Research 41.08 (2009): 594-599.

14 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Methylglyoxal and Small Heat Shock Proteins.
Sudnitsyna MV, Gusev NB., Biochemistry (Mosc) 82(7), 2017
PMID: 28918740
Hyperglycemic Stress and Carbon Stress in Diabetic Glucotoxicity.
Luo X, Wu J, Jing S, Yan LJ., Aging Dis 7(1), 2016
PMID: 26816666
Impaired Chaperone Activity of Human Heat Shock Protein Hsp27 Site-Specifically Modified with Argpyrimidine.
Matveenko M, Cichero E, Fossa P, Becker CF., Angew Chem Int Ed Engl 55(38), 2016
PMID: 27440458
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.
Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC., JACC Heart Fail 3(2), 2015
PMID: 25660838
The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases.
Maessen DE, Stehouwer CD, Schalkwijk CG., Clin Sci (Lond) 128(12), 2015
PMID: 25818485
The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure.
Riggs K, Ali H, Taegtmeyer H, Gutierrez AD., Metab Syndr Relat Disord 13(7), 2015
PMID: 26125313
Role of glyoxalase I in the proliferation and apoptosis control of human LNCaP and PC3 prostate cancer cells.
Antognelli C, Mezzasoma L, Fettucciari K, Mearini E, Talesa VN., Prostate 73(2), 2013
PMID: 22653787
Impact of GLO1 knock down on GLUT4 trafficking and glucose uptake in L6 myoblasts.
Engelbrecht B, Stratmann B, Hess C, Tschoepe D, Gawlowski T., PLoS One 8(5), 2013
PMID: 23717693
Diabetic cardiomyopathy--to take a long story serious.
Stratmann B, Gawlowski T, Tschoepe D., Herz 35(3), 2010
PMID: 20467928

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 19384818
PubMed | Europe PMC

Suchen in

Google Scholar